Sutro Biopharma is undergoing a seismic shake-up —jettisoning its CEO, half of its workforce, its lead candidate and its ...

Sutro Biopharma (Nasdaq: STRO), a US biotechnology company, has announced significant organizational changes, including a ...

Sutro’s stock tumbled nearly 19% after the company announced it will sideline its FRα-targeted antibody-drug conjugate ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its ...

Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Dr. Michael Ge, CEO of Kelun-Biotech said, "We are very pleased that the second indication of the Company's TROP2 ADC sacituzumab tirumotecan has been approved for marketing, which is exciting ...